Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LIVN vs KIDS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LIVN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

LIVN Overall Winner 6-Pillar Tally: LIVN 4 – 2 KIDS Matrix Metrics: LIVN 7 – 3 KIDS

As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LIVN carries a Unified Composite Score of 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin).

  • Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. -8.2% operating margin) and revenue trajectory (+9.9% vs. +18.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LIVN vs KIDS
LIVN NASDAQ Head-to-Head Winner
LivaNova PLC Ordinary Shares
Electromedical & Electrotherapeutic Apparatus
$92.07
-2.61% 1D
Market Cap $5.1B
TTM Revenue $1.51B
Forward P/E 19.5x
Beta / 30D Vol 0.98β · 67% Vol
Unified Composite Score
38.5 / 100 SELL
Tech 23.0 Fund 40.0 Flow 70.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $87.27 · SMA50: $81.35
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86

6-Pillar Scorecard Institutional Category Breakdown (LIVN 4 – 2 KIDS)

Columns: Metric · LIVN · KIDS
1. Valuation Multiples LIVN
Forward P/E 19.5x N/M
Trailing P/E 26.5x N/M
PEG Ratio 0.93x N/M
EV / Revenue 3.2x 3.2x
2. Growth & Scale KIDS
Revenue Growth (YoY) +9.9% +18.6%
Earnings Growth (YoY) -78.2% +0.0%
TTM Revenue (USD) $1.51B $264M
Market Cap $5.1B $850.2M
3. Profitability & Quality LIVN
Gross Margin 67.6% 73.8%
Operating Margin 14.3% -8.2%
Net Profit Margin 13.0% -12.8%
Return on Equity (ROE) 15.5% -9.8%
4. Balance Sheet & Cash Flow LIVN
Cash Generation (TTM) $129M $1.1M EBITDA
Cash Flow Margin 8.6% 0.4% EBITDA Mgn
Net Cash / Leverage $206M Net Cash $12.99 Book/Sh · -9.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LIVN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 36.9% (11th %ile) 145.1% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 53.3% of Rev ($803M) 82.0% of Rev ($217M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LIVN (7) vs KIDS (3)
Institutional Metric LIVN KIDS Criterion Row Edge
Market Capitalization
Scale
$5.1B $850.2M Larger Scale LIVN
Trailing P/E Ratio
Valuation
26.5x N/M Lower Multiple LIVN
Forward P/E Ratio
Valuation
19.5x N/M Lower Multiple LIVN
Revenue Growth (YoY)
Growth
+9.9% +18.6% Higher Growth KIDS
Operating Margin (TTM)
Profitability
14.3% -8.2% Higher Margin LIVN
Net Profit Margin
Profitability
13.0% -12.8% Higher Margin LIVN
Return on Equity (ROE)
Capital Efficiency
15.5% -9.8% Higher ROE LIVN
52-Week Range Position
Momentum
84% ($52–$99) 90% ($14–$35) Stronger Trend KIDS
Beta / 30D Volatility
Risk Regime
0.98β · 67% Vol 0.81β · 108% Vol Lower Realized Risk LIVN
Unified Institutional Score
Composite Signal
38.5 / 100 (SELL) 45.1 / 100 (HOLD) Higher Composite KIDS
Trailing 12M Revenue (USD)
Operating Scale
$1.51B $264M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.6% 73.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 3.2x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$129M ($206M Net Cash) $1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KIDS +18.99 pp
LIVN: +17.38% · KIDS: +36.37%
3M Horizon KIDS +9.81 pp
LIVN: +16.93% · KIDS: +26.74%
6M Horizon KIDS +51.37 pp
LIVN: +25.03% · KIDS: +76.4%
1Y Horizon KIDS +27.99 pp
LIVN: +70.85% · KIDS: +98.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LIVN vs KIDS. Trailing 12-month operating profitability (LIVN 14.3% vs KIDS -8.2%) and valuation multiples (LIVN 19.5x vs KIDS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LIVN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.51B
Gross Margin67.6%
Op. Margin14.3%
ROE / Fwd P/E15.5% · 19.5x
KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LIVN CONSOLIDATION
97d in phase · OBV NEUTRAL
Current IV 36.9%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LIVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LIVN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.1B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 53.3% of Rev ($803M)
90D Engineering Disclosures 0 Published
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published

Investor FAQ LIVN vs KIDS Key Questions & Quantitative Answers

As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LIVN carries a Unified Composite Score of 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin). Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. -8.2% operating margin) and revenue trajectory (+9.9% vs. +18.6% YoY).

KIDS leads the Growth & Scale pillar: LIVN posts +9.9% YoY revenue growth and -78.2% YoY earnings growth on $1.51B TTM revenue (67.6% gross margin, 14.3% operating margin), compared with KIDS at +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin). On trailing 12-month operating scale, LIVN generates $1.51B in USD-normalized revenue versus $264M for KIDS. In operating R&D and SG&A reinvestment, LIVN deploys 53.3% of Rev ($803M) (0 90-day corporate R&D disclosures) versus 82.0% of Rev ($217M) (0 disclosures) for KIDS.

LIVN screens cheaper on headline valuation multiples. LIVN trades at 19.5x Forward P/E, 26.5x Trailing P/E, 0.93x PEG, and 3.2x EV/Revenue (8.6% FCF margin), whereas KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LIVN (15.5% ROE) versus KIDS (-9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LIVN carries 36.9% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.98β · 67% Vol realized risk). By comparison, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.